In the last trading session, 4.77 million Gilead Sciences Inc. (NASDAQ:GILD) shares changed hands as the company’s beta touched 0.39. With the company’s per share price at $67.05 changed hands at -$0.3 or -0.45% during last session, the market valuation stood at $84.86B. GILD’s last price was a discount, traded about -17.73% off its 52-week high of $78.94. The share price had its 52-week low at $56.56, which suggests the last value was 15.65% up since then. When we look at Gilead Sciences Inc.’s average trading volume, we note the 10-day average is 8.35 million shares, with the 3-month average coming to 7.15 million.
Analysts gave the Gilead Sciences Inc. (GILD) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.40. If we narrow down to specifics, the data shows that 2 out of 29 analysts rate the stock as a Sell, with a further 2 assigning it an Overweight rating. Of the remaining, 13 recommended GILD as a Hold, 12 felt it is a Buy and 0 rated the stock as Underweight. Gilead Sciences Inc.’s EPS for the current quarter is expected to be $1.73.
Gilead Sciences Inc. (NASDAQ:GILD) trade information
Instantly GILD was in red as seen at the end of in last trading. With action -1.53%, the performance over the past five days has been red. The drop to weekly highs of 69.34 on Tuesday, 06/22/21 subtracted -0.45% to the stock’s daily price. The company’s shares are showing year-to-date upside of 15.09%, with the 5-day performance at -1.53% in the red. However, in the 30-day time frame, Gilead Sciences Inc. (NASDAQ:GILD) is -2.47% down. Looking at the short shares, we see there were 23.69 million shares sold at short interest cover period of 3.11 days.
The consensus price target for the stock as assigned by Wall Street analysts is $75.08, meaning bulls need an upside of 10.7% from its current market value. According to analyst projections, GILD’s forecast low is $60.00 with $100.00 as the target high. To hit the forecast high, the stock’s price needs a -49.14% plunge from its current level, while the stock would need to tank 10.51% for it to hit the projected low.
Gilead Sciences Inc. (GILD) estimates and forecasts
Data shows that the Gilead Sciences Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 13.49% over the past 6 months, a -0.28% in annual growth rate that is considerably lower than the industry average of 9.00%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Gilead Sciences Inc. will rise 55.90%, while the growth in revenue is estimated to hit -20.90% for the next quarter. Year-over-year growth is forecast to reach -0.10% down from the last financial year.
Consensus estimates given by 18 financial analysts project the company’s revenue in the current quarter to hit an average of $6.09 billion. 18 analysts are of the opinion that Gilead Sciences Inc.’s revenue for the quarter ending Sep 2021 will be $6.02 billion. The estimates for the next quarter sales put growth at -8.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -61.80%. The 2021 estimates are for Gilead Sciences Inc. earnings to decrease by -97.70%, but the outlook for the next 5-year period is at 2.98% per year.
Gilead Sciences Inc. is expected to release its next quarterly earnings report in July. The 4.24% annual yield figure for the share gives it an annual dividend of 2.84. It is important to note, however, that the 4.24% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 3.27 per year.
Gilead Sciences Inc. (NASDAQ:GILD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.10% of Gilead Sciences Inc. shares while 80.65% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 80.73%. There are 80.65% institutions holding the Gilead Sciences Inc. stock share, with Blackrock Inc. the top institutional holder. As of Mar 30, 2021, the company held 9.94% of the shares, roughly 124.72 million GILD shares worth $8.06 billion.
Capital Research Global Investors holds the second largest percentage of outstanding shares, with 9.78% or 122.61 million shares worth $7.92 billion as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and American Mutual Fund Inc. With 35.32 million shares estimated at $2.28 billion under it, the former controlled 2.82% of total outstanding shares. On the other hand, American Mutual Fund Inc held about 2.50% of the shares, roughly 31.38 million shares worth around $2.03 billion.